Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Immunoblastic Lymphadenopathy 1Gastro-enteropancreatic neuroendocrine tumor 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 8Cetuximab 8Cisplatin 6Fluorouracil 5Paclitaxel 4durvalumab 3Radiotherapy 3Leucovorin 3Docetaxel 3Carboplatin 3tremelimumab 2niraparib 2avelumab 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Nivolumab 2Ipilimumab 2Bevacizumab 2zalutumumab 1yeast-CEA vaccine 1spartalizumab 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1regorafenib 1penpulimab 1paclitaxel poliglumex 1osimertinib 1necitumumab 1dostarlimab 1demplatin pegraglumer 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Squamous Cell × Clinical Trials, Phase II as Topic × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡